Results 171 to 180 of about 291,785 (296)

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology

Advanced Science, EarlyView.
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu, Jinqiu Liu, Yuxuan Deng, Shuyu Hao, Xiaoli Zhang, Mingxu Yang, Chao Guo, Chao Du, Yingdan Chen, Tai Sun, Nan Ji, Zhengping Zhuang, Jie Feng   +12 more
wiley   +1 more source

TRAF6 Lactylation in Glycolytic Macrophages Drives NF‐κB Signaling and M1 Polarization During Orthodontic Tooth Movement

Advanced Science, EarlyView.
Schematic diagram showing compressive stress triggers glycolytic reprogramming and lactate accumulation in macrophages. Lactate mediates TRAF6 lactylation at K171/K180 dual sites, which enhances its K63‐linked ubiquitination to activate the NF‑κB pathway and promote M1 polarization. This cascade drives orthodontic tooth movement (OTM) and alveolar bone
Xinyi He, Guodong Zhao, Yun Hu, Wenya Bai, Hao Tan, Shuai Yuan, Sihan Yang, Ye Zhu, Xiaohui Xu, Leilei Zheng   +9 more
wiley   +1 more source

CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer cell lines of differing origins were cultured over many passages while being subjected to semi‐lethal levels of fluid shear stress, representing the harsh mechanical environment these cells are subjected to in the circulation during the process of distant metastasis.
Abigail R. Fabiano, Allen C. Luo, Paul Taufalele, Jenna A. Dombroski, Ehsan Aalaei, Schyler J. Rowland, Melissa S. Cantú, Alexandria T. Carter, Samantha V. Knoblauch, Cynthia A. Reinhart‐King, Michael R. King   +10 more
wiley   +1 more source

Chemotherapy and checkpoint blockade [PDF]

Nature Reviews Urology, 2018
openaire   +1 more source

Checkpoint blockade in FL: eluding the king [PDF]

Blood, 2021
openaire   +2 more sources

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Advanced Science, EarlyView.
This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu, Zhijun Qin, Jiapeng Yang, Baoyuan Zhang, Manqing Cao, Peng Wang, Zaiqi Wang, Jinghui Cheng, Lei Wang, Hong Liu, Hui Yang   +10 more
wiley   +1 more source

Real-World Comparison of Dual Checkpoint Blockade and Immunotherapy Plus TKIs in Metastatic RCC. [PDF]

Cancer Med
Ohba K, Oki M, Matsuda T, Miyata H, Kikuchi H, Inoue T, Shin T, Sekine Y, Narita S, Naito S, Tsuchiya N, Naito H, Sugimoto M, Numakura K, Kobayashi S, Ueda K, Igawa T, Mitsunari K, Matsuo T, Imamura R.   +19 more
europepmc   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade. [PDF]

Front Immunol
Wang X, Gao W, Wang Q, He S, Cui S, Duan B, Ding G, Huang Y, Zou B.   +8 more
europepmc   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source